Home > Oncology > Ipilimumab prolongs overall survival in metastatic castration-resistant prostate cancer

Ipilimumab prolongs overall survival in metastatic castration-resistant prostate cancer

Journal
European Urology
Reuters Health - 08/09/2020 - Treatment with ipilimumab following radiotherapy to bone metastases in men with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel is associated with improved overall survival, according to final results from the CA184-043 trial. "This should prompt us to start revisiting immunotherapy in mCRPC," Dr. Karim Fizazi of Institut Gustav Roussy, University of Paris Saclay, in Villejuif, told Reuters Health by email. "Using immunotherapy was almost stopped 5 years ago after two phase-3 trials had failed to demonstrate overall survival improvement. These data indicate that some men clearly benefit and also that early assessments of survival may not be appropriate to assess immunotherapy benefits." The monoclonal antibody ipilimumab blocks the inhibitory signal mediated by CTLA-4, thereby enhancing antitumor immunity at the expense of immune-related side effects. In earlier trials, including 043, ipilimumab...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on